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Background-—The relationship between structural pathology and electrophysiological substrate in cardiac amyloidosis is unclear.
Differences between light-chain (AL) and transthyretin (ATTR) cardiac amyloidosis may have prognostic implications.
Methods and Results-—ECG imaging and cardiac magnetic resonance studies were conducted in 21 cardiac amyloidosis patients
(11 AL and 10 ATTR). Healthy volunteers were included as controls. With respect to ATTR, AL patients had lower amyloid volume
(51.0/37.7 versus 73.7/16.4 mL, P=0.04), lower myocardial cell volume (42.6/19.1 versus 58.5/17.2 mL, P=0.021), and higher
T1 (1172/64 versus 1109/80 ms, P=0.022) and T2 (53.4/2.9 versus 50.0/3.1 ms, P=0.003). ECG imaging revealed differences
between cardiac amyloidosis and control patients in virtually all conduction-repolarization parameters. With respect to ATTR, AL
patients had lower epicardial signal amplitude (1.07/0.46 versus 1.83/1.26 mV, P=0.026), greater epicardial signal fractionation
(P=0.019), and slightly higher dispersion of repolarization (187.6/65 versus 158.3/40 ms, P=0.062). No significant difference
between AL and ATTR patients was found using the standard 12-lead ECG. T1 correlated with epicardial signal amplitude
(cc=0.78), and extracellular volume with epicardial signal fractionation (cc=0.48) and repolarization time (cc=0.43). Univariate
models based on single features from both cardiac magnetic resonance and ECG imaging classified AL and ATTR patients with an
accuracy of 70% to 80%.
Conclusions-—In this exploratory study cardiac amyloidosis was associated with ventricular conduction and repolarization
abnormalities, which were more pronounced in AL than in ATTR. Combined ECG imaging–cardiac magnetic resonance analysis
supports the hypothesis that additional mechanisms beyond infiltration may contribute to myocardial damage in AL amyloidosis.
Further studies are needed to assess the clinical impact of this approach. ( J Am Heart Assoc. 2019;8:e012097. DOI: 10.1161/
JAHA.119.012097.)
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C ardiac amyloidosis is a disorder characterised by thedeposition of abnormal protein fibers known as amyloid
fibrils that can lead to heart failure and sudden cardiac death.
Electrophysiological abnormalities and their relation to struc-
tural pathology are not well characterized in this population
despite the fact that amyloid infiltration can induce complete
heart block and has been linked to ventricular arrhythmias.1-3
The most common forms of cardiac amyloidosis are due to
precursor proteins transthyretin (ATTR)4 and immunoglobulin-
derived light chains (AL),5 with cardiac involvement being the
main driver of prognosis in both.6 Amyloid infiltration in cardiac
ATTR amyloidosis is usually more severe than in AL, resulting in
higher left ventricular (LV) mass and more severe systolic and
diastolic dysfunction in ATTR.7 However, in AL amyloidosis the
survival is significantly worse, with median survival from
presentation of about 6 months as opposed to 6 years in
From the Barts Heart Centre, Barts Health NHS Trust, London, United Kingdom (M.O., A.J.G., P.D.L.); Institute of Cardiovascular Science, University College London,
London, United Kingdom (M.O., P.D.L.); The Royal Free Hospital, UCL Hospitals Trust, London, United Kingdom (A.M.-N., P.N.H., M.F.); Cardiac Bioelectricity and
Arrhythmia Center, Washington University in St Louis, St. Louis, MO (C.M.A., Y.R.); MRC London Institute of Medical Sciences, Imperial College London, London, United
Kingdom (A.d.M., B.S., S.A.C., D.P.O.).
Accompanying Tables S1 through S3 are available at https://www.ahajournals.org/doi/suppl/10.1161/JAHA.119.012097
*Dr Orini and Dr Graham contributed equally to this work as co–first authors.
†Dr Fontana and Dr Lambiase contributed equally to this work as co–senior authors.
Correspondence to: Pier D. Lambiase, PhD, FRCP, FHRS, Cardiology Department, Barts Heart Centre, Barts Health NHS Trust, West Smithfield, London EC1A 7BE,
United Kingdom. E-mail: p.lambiase@ucl.ac.uk
Received January 19, 2019; accepted July 30, 2019.
ª 2019 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the Creative Commons
Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.





 http://ahajournals.org by on October 2, 2019
ATTR,6 and the rate of sudden cardiac death is significantly
higher, occurring in a third of cases within the first 90 days.8
This divergence between phenotypic severity and outcome
remains poorly understood but has been ascribed to
additional toxic effects of AL amyloid9 or to a faster rate of
amyloid deposition in AL compared with ATTR,8 leading to
more severe myocardial damage in AL.
Cardiac magnetic resonance (CMR) has been proven to be
able to measure the continuum of amyloid infiltration and the
myocardial response, both in terms of myocyte loss/myocyte
hypertrophy and myocardial edema, providing a deeper under-
standing of disease pathogenesis and of the differences
between the 2 main types of amyloidosis.7,10-14 However,
neither the ventricular electrophysiological (EP) substrate
associated with cardiac amyloid deposition nor the potential
EP differences between AL and ATTR have ever been charac-
terized, leaving a critical knowledge gap in disease understand-
ing. Electrocardiographic imaging (ECGI)15,16 is a noninvasive
technology that computes epicardial extracellular potentials
and provides insight into potential arrhythmogenic sub-
strates.17-20 We conducted an exploratory CMR-ECGI study to
investigate for the first time the interaction between EP and
structural abnormalities associated with cardiac amyloidosis
and to determine how these may differ between AL and ATTR.
Methods
The data that support the findings of this study are available
from the corresponding author on reasonable request.
Study Population
Twenty-one patients with cardiac amyloidosis (11 AL and 10
ATTR) were prospectively recruited and underwent ECGI and
CMR studies at The Royal Free Hospital, University College
London Hospitals, United Kingdom. Cardiac ATTR amyloidosis
was defined as the combination of symptoms with an echocar-
diogram consistent with or suggestive of cardiac amyloidosis,21
a grade 2 or 3 cardiac uptake on 99mTc-DPD (3,3-diphosphono-
1,2-propanodicarboxylic acid) scintigraphy in the absence of a
monoclonal gammopathy, or, in the presence of monoclonal
gammopathy, a cardiac biopsy confirming ATTR.22 All subjects
underwentsequencingofexons2,3,and4of theTTRgene.Of the
10 ATTR patients, 8 were wild type, and 2 had hereditary ATTR
associated with the V122I variant. Cardiac AL amyloidosis was
determined on the basis of international consensus criteria23 as
well as the combination of typical features on CMR and biopsy-
proven systemic AL amyloidosis on cardiac or noncardiac
biopsy.22 All enrolled patients provided informed consent to
participate in the research. The study was approved by the
National Research Service Committee, London (14/LO/0360).
Patients’ age, sex, etiology, and medication(s) are reported in
Table S1.
Two groups of healthy volunteers were recruited: 1 served as
control for CMR parameters (n=25 patients), and the other
served as control for 12-lead ECG and ECGI parameters (n=30
patients).
ECGI Protocol and Analysis
ECGI provides noninvasive assessment of epicardial electro-
physiology and has been described previously.15,20 Briefly,
256 electrodes were placed to uniformly cover the patient’s
torso (ActiveTwo, BioSemi, Santiago, Chile), and body surface
potentials were recorded at a sampling frequency of 2048 Hz
for 5 minutes at rest in a supine position. Electrodes were
then removed and replaced with magnetic resonance imaging
opaque markers positioned in identical locations before a
CMR scan was performed to acquire heart-torso geometries.
Data were exported and analyzed offline. Epicardial meshes
and electrode locations on the torso were reconstructed using
commercial software (Amira, ThermoFisher, Waltham, MA).
Signal averaging was performed to enhance the signal quality
of body surface potentials using custom software (Matlab,
MathWorks, Natick, MA). Unipolar epicardial electrograms
were reconstructed by solving the inverse problem of
electrocardiography.15,16,20 Typically, 1000 electrograms
were computed over the entire ventricular epicardium, with
those over the valve plane excluded from analysis. At each
cardiac site, activation (AT) and repolarization times (RT) were
measured as the time of the steepest signal downslope (dV/
dtmin) during the QRS complex and the time of steepest signal
Clinical Perspective
What Is New?
• This is the first combined assessment of the electrical and
structural ventricular substrate in cardiac amyloidosis
patients, integrating data from advanced cardiac magnetic
resonance imaging with recently proposed ECG imaging.
• This study demonstrates for the first time an interaction
between cardiac magnetic resonance imaging indices (T1,
T2, and extracellular volume) and ECG imaging features
(signal amplitude, activation, and repolarization heterogene-
ity), and results suggest that several structural and
functional parameters are different in AL and ATTR patients
and could be used to discriminate between these 2 groups.
What Are the Clinical Implications?
• This novel approach may provide a better understanding of
the underlying pathophysiology and enable more accurate
prognosis in cardiac amyloidosis as well as track treatment
effects, but further studies are needed to fully determine its
clinical implications.
DOI: 10.1161/JAHA.119.012097 Journal of the American Heart Association 2
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upslope (dV/dtmax) during the T-wave, respectively. Cardiac
intervals were referenced to the earliest AT and were carefully
reviewed and corrected with semiautomatic custom software
as in previous studies.24-26 Figure 1A shows a representative
AT map from an ATTR patient, and panels B and C report
examples of unipolar electrograms from 2 different sites.
Activation-recovery interval (ARI), a standard surrogate for
action potential duration,27 was measured as ARI=RT–AT.
Repolarization times were corrected for heart rate using the
Fridericia formula. Global dispersion of AT, RT, and ARI (DAT,
DRT, and DARI, respectively) was measured as the difference
between the maximum and minimum value of AT, RT, and ARI,
respectively, across the entire epicardium. Spatial gradients
of activation (GAT) were measured as the absolute AT
difference between neighboring sites divided by their dis-
tance, averaged across all neighbors.20 Spatial gradients of
repolarization (GRT) were measured similarly. Epicardial signal
amplitude was measured as peak-to-peak amplitude, ie, the
difference between the maximum and the minimum (which
can be negative) values within the QRS complex of the
unipolar electrogram (Figure 1D). Signal fractionation, an
indication of underlying abnormal electrical activity,28 was
quantified by the number of negative deflections during the
QRS complex (Figure 1D).
CMR Protocol and Analysis
All participants underwent standard CMR on a 1.5 T scanner
(Aera, Siemens Healthcare, Erlangen, Germany). A standard
clinical scan protocol with late gadolinium enhancement
imaging and T1 mapping (by Modified Look-Locker Inversion
recovery) before and after a bolus of gadolinium contrast
(0.1 mmol/kg of gadoterate meglumine) was performed.29
Late gadolinium enhancement imaging was acquired using
Figure 1. Representative example of epicardial potentials in cardiac amyloidosis reconstructed by ECGI. A,
Local activation time (LAT) map in different angiographic views. B and C, Unipolar electrograms (continuous
lines) from cardiac sites P1 and P2. Dots represent activation and repolarization times, and dashed lines
represent local action potentials (schematic, for illustration purposes only). D, Unipolar electrogram from
cardiac site P3 exhibiting fractionatedQRS complexwith 4 negative deflections (bold gray line) and low voltage.
Amplitude (Amp) is measured as the difference between the maximum and minimum values of the unipolar
electrogram within the QRS complex (vertical dashed line). AT indicates activation time; ECGI, ECG imaging;
LAO, Left Anterior Oblique; RAO, Right Anterior Oblique; RT, repolarization time; UEG, Unipolar Electrogram.
DOI: 10.1161/JAHA.119.012097 Journal of the American Heart Association 3
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magnitude reconstruction and phase-sensitive inversion recov-
ery reconstruction in all patients. Postcontrast T1 mapping was
performed 15 minutes after the administration of gadolinium.
All CMR images were analyzed offline. Left ventricular volumes,
mass, and function were analyzed using in-house plugins on
OsiriX, version 9.0.1 (Pixmeo SARL, Bernex, Switzerland). For T1
mapping, 4-chamber and 3-short-axis maps (base, middle, and
apex) were acquired. The 3-short-axis T1 maps were manually
contoured at the endocardial and epicardial border, segmented
into an American Heart Association 16-segment model using
the right ventricular insertion points. Hematocrit (h) was
measured in all subjects immediately before each CMR study.
As in previous studies,7,11,14 extracellular volume (ECV) was
calculated as (1h)9DR1myocardium/DR1bloodpool, whereDR1 is
the difference in relaxation rates (1/T1) precontrast and
postcontrast, and total myocardial amyloid volume was calcu-
lated as LV mass/g9ECV, where g is the specific gravity of
myocardium (1.05 g/mL). Total myocardial cell volume was
calculated as LV mass/g9(1ECV). For T2 mapping, 3-short-
axis matching the T1 maps was acquired and analyzed in the
same way as the T1 maps.
Standard 12-Lead ECG
A 12-lead ECG was recorded, and standard parameters were
derived. QRS amplitude was measured as the average of peak-
to-peak QRS amplitude in limb, precordial, and all leads,
respectively.30 Patients were classified as showing low QRS
amplitude if the amplitudewas<0.5 mV in all limb leadsor<1 mV
in all precordial leads. Additionally, Sokolow criteria,31 in which
QRS low amplitude is defined as the sum of S-wave in V1 and R-
wave in V5 or V6 lower than 1.5 mV, was also implemented.
Statistical Analyses
Analyses of CMR and ECGI data were blind to cardiac
amyloidosis pathology (AL and ATTR) but not to controls, as
these patients were recruited at a further stage of the study.
Continuous variables are presented as median/interquartile
range. The Wilcoxon rank-sum test was used to test unpaired
comparisons with statistical significance set at P<0.05. Given
the exploratory nature of the study and the expected correla-
tion among several variables, corrections for multiple compar-
isons were not performed.32 The statistical significance of the
reported associations should be confirmed in future confirma-
tory studies. Correlation was assessed using the Spearman
correlation coefficient. For variables presenting multiple values
per patient (eg, 1 value per cardiac site or per anatomical
segment), differenceswere evaluated between themean values
representing the within-patients distribution. Correlations
between EP and structural substrates were assessed by
measuring the correlation coefficient between the mean ECGI
Table 1. CMR Parameters Expressed as Median (Interquartile Range) or Number (Proportion)
CMR Parameters Amyloid (n=21) Controls (n=25) P Value AL (n=11) ATTR (n=10) P Value
Age, y 73.0 (19.2) 45.3 (12.6) 4.00E-08* 64.0 (8.5) 80.5 (7.0) 1.1E-02*
Male (n) 19 (90) 19 (80) 4.20E-01 81.8 100 4.8E-01
ECV (%) 51.6 (9.0) 0.3 (0.0) 2.30E-07* 49.7 (7.8) 52.4 (11.3) 4.5E-01
T1, ms 1155 (79) 989.8 (32.5) 1.60E-08* 1172 (64) 1109 (80) 2.2E-02*
T2, ms 52.6 (4.2) 48.0 (2.3) 8.40E-06* 53.4 (2.9) 50.0 (3.1) 3.0E-03*
LVEF, % 62 (16.5) 65.5 (6.0) 2.10E-01 58 (13.8) 70 (14.0) 5.7E-02
LVEDV, mL 138 (56.8) 175.5 (70.0) 8.10E-03* 147 (66.5) 135 (28.0) 4.2E-01
LVEDVi, mL/m2 71 (26.0) 87.5 (20.0) 7.00E-03* 72 (34.5) 66 (20.0) 2.9E-01
LVESV, mL 49 (33.8) 62.5 (33.0) 2.80E-01 57 (31.8) 38 (28.0) 5.7E-02
LVESVi, mL/m2 26 (18.8) 29.0 (10.0) 4.40E-01 30 (12.5) 18 (14.0) 5.2E-02
LV-SV, mL 81 (29.0) 117.0 (32.0) 6.40E-05* 80 (31.0) 82 (26.0) 8.3E-01
LV-SV-i, mL/m2 41 (10.3) 57.5 (10.0) 2.60E-05* 41 (9.8) 42 (10.0) 8.9E-01
LV mass, g 250 (97.1) 117.0 (55.0) 2.00E-06* 196 (114.0) 270 (69.0) 2.2E-02*
LV mass-i, mL/m2 127 (40.8) 58.5 (20.0) 2.60E-07* 104 (51.3) 136 (24.0) 4.1E-02*
TAPSE, mm 15.0 (10.3)   13.0 (15.0) 15.5 (6.0) 9.2E-01
Total amyloid volume, mL 68.1 (29.5) 31.9 (11.9) 1.50E-04* 51.0 (37.7) 73.7 (16.4) 4.5E-02*
Total cell volume, mL 50.5 (20.4) 83.2 (40.1) 9.00E-05* 42.6 (19.1) 58.5 (17.2) 2.1E-02*
AL indicates light-chain amyloidosis; ATTR, transthyretin amyloidosis; CMR, cardiac magnetic resonance; ECV, mean extracellular volume; EF, ejection fraction; ESV and EDV, end-systolic and
-diastolic volume, respectively; LV, left ventricle; SV, stroke volume; TAPSE, mean tricuspid annular plane systolic excursion; indices followed by “-i” are indexed to body surface volume.
*P<0.05.
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and CMR parameters obtained by averaging over common
anatomical segments (because ECGI and CMR provide epicardial
and LV information, respectively, right ventricular segments were
excluded from ECGI, and septal segments were excluded from
CMR parameters). The standard 17-segment model was used to
identify commonsegments in the2modalities. Logistic regression
wasused to classify AL andATTRpatients.Univariatemodelswere
constructed using the subset of features that showed differences
between AL and ATTR patients associated with P<0.10 (Wilcoxon
rank sum test), and the least absolute shrinkage and selection
operatormethodwas used to identify themost suitable subsets of
features to be tested in multivariate models. Cross validation was
performed to assess possible issues related to overfitting using
the leave-1-out technique. Accuracies achieved by different
models were compared with the McNemar test.
Results
Cardiac amyloidosis patients were predominantly male (81.8%
of AL and 100% of ATTR), and ATTR were older than AL
patients (80.5/7 versus 64/8.5 years, P=0.01, median/
interquartile range).
CMR Imaging Findings
With respect to healthy controls, cardiac amyloidosis patients
(both AL and ATTR) showed expected abnormalities, including
higher ECV, T1, T2, LV mass, and diastolic impairment
(Table 1). Differences were also observed between AL and
ATTR patients. ECV was elevated in patients with both AL and
ATTR amyloidosis (P=0.45, Table 1). LV mass (196/114.0 g
versus 270/69.0 g, P=0.02), total myocardial amyloid volume
(51.0/37.7 versus 73.7/16.4 mL, P=0.04), and myocardial
cell volume (42.6/19.1 versus 58.5/17.2 mL, P=0.021) were
higher in ATTR than in AL patients, whereas T1 (1172/64
versus 1109/80 ms, P=0.022) and T2 (53.4/2.9 versus
50.0/3.1 ms, P=0.003) were higher in AL than ATTR. LV
ejection fraction was slightly lower in AL than in ATTR (58/
13.8% versus 70/14.0%, P=0.06), mainly because of slightly
larger end-systolic volume in AL (57/31.8 mL versus 38/
Figure 2. Late gadolinium enhancement (LGE), extracellular volume (ECV), native T1 and T2 maps for ATTR (top), AL (middle), and control
(bottom) patients. ECV, T1, and T2 are higher in the 2 amyloid patients than in the control patient. T1 and T2 are higher in the AL than in the
ATTR patient despite similar degree of cardiac amyloid infiltration (similar ECV). AL indicates light-chain amyloidosis; ATTR, transthyretin
amyloidosis; T1 and T2, magnetic fields in magnetic resonance imaging.
DOI: 10.1161/JAHA.119.012097 Journal of the American Heart Association 5
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28.0 mL, P=0.06). Figure 2 shows late gadolinium enhance-
ment, ECV, and T1 and T2 maps in patients with AL and ATTR
amyloidosis as well as in a control patient.
Surface ECG Findings
Standard surface ECG analysis showed that with respect to
controls, cardiac amyloidosis patients had wider QRS (106/17
versus 88/12 ms, P<0.005), longer PR interval (185/55 versus
160/26 ms, P<0.005), longer QTc (444/38 versus 415/
28 ms, P=0.008), and lower QRS amplitude in all lead
configurations (Table 2). The interval from the end of the QRS
to the end of the T wave (measured as QTc–QRS) was not
significantly different in cardiac amyloidosis patients as com-
pared with control patients (P=0.73), suggesting that QTc
prolongation could be explained by a widening of the QRS
complex. T-wave inversion and poor R-wave progression were
more frequent in cardiac amyloidosis than in controls. No
surface ECG parameter showed statistically significant differ-
ences between AL and ATTR patients (Table 2). Because
differences in EP parameters may be explained by age (73/
19 years in cardiac amyloidosis versus 31/31 years in con-
trols, P<0.005), a secondary analysis was performed by
comparing 10 cardiac amyloidosis patients (5 ATTR+5 AL) with
10 age-matched controls. Results were in agreementwith those
between amyloidosis patients and younger volunteers with the
exception that although median QTc was still longer in cardiac
amyloidosis, this differencewas no longer significant (Table S2).
Ventricular EP Abnormalities in Cardiac
Amyloidosis
Figure 3 shows EP differences in representative control, AL,
and ATTR patients. Cardiac amyloidosis patients presented
multiple severe EP abnormalities (Table 3, Figure 3). With
respect to healthy volunteers, epicardial signal amplitude was
markedly reduced (1.15/0.82 versus 1.96/0.89 mV,
P<0.001), intraventricular conduction was slower (total acti-
vation time equal to 65.4/24.7 versus 41.5/11.7 ms,
P<0.001), and markers of conduction abnormality were
higher (epicardial signal fractionation equal to 1.18/0.11
versus 1.10/0.10, P<0.001, spatial gradient of activation
equal to 0.35/0.14 versus 0.23/0.08 ms/mm, all P<0.001).
Furthermore, all repolarization parameters demonstrated a
longer and more spatially dispersed repolarization process in
cardiac amyloidosis than in controls (eg, ARI equal to 283.2/
23.4 versus 242.6/24.8 ms, P<0.001, DARI=180.2/63.0
versus 1432/19.6 ms, P<0.001). In secondary analysis,
comparison between cardiac amyloidosis patients (5 ATTR+5
AL) and 10 age-matched controls showed similar results, with
all differences remaining significant despite a reduction in
statistical power (Table S3).
Ventricular EP Differences Between AL and ATTR
As shown in the example reported in Figure 3, epicardial
abnormalities were more pronounced in AL than in ATTR
Table 2. Twelve-Lead ECG Parameters
Surface ECG Parameters Amyloid (n=21) Controls (n=30) P Value Amyloid AL (n=11) Amyloid ATTR (n=10) P Value
AF (n) 3 (14.3%) 0 (0.0%) 6.39E-02 1 (9.1%) 2 (20.0%) 1.00E+00
RR, ms 886 (187.5) 938 (126.5) 2.75E-01 822 (219.0) 897 (164.0) 6.20E-02
QRS, ms 106 (17.0) 88 (12.0) 3.03E-05* 104 (14.0) 107 (20.0) 6.70E-01
PR, ms 185 (55.0) 160 (26.5) 9.35E-04* 185 (22.0) 199 (94.0) 6.00E-01
QT, ms 444 (38.1) 415 (28.1) 7.59E-03* 433 (65.0) 450 (27.6) 2.80E-01
Poor R progression (n) 17 (81.0%) 1 (3.3%) 6.48E-09* 11 (100.0%) 6 (60.0%) 3.51E-02*
BBB (n) 3 (14.3%) 0 (0.0%) 6.39E-02 2 (18.2%) 1 (10.0%) 1.00E+00
TW inversion (n) 8 (38.1%) 0 (0.0%) 3.20E-04* 5 (45.5%) 3 (30.0%) 7.00E-01
Amp-limb, mV 0.40 (0.21) 0.95 (0.37) 1.99E-07* 0.37 (0.21) 0.41 (0.37) 4.38E-01
Amp-precordial, mV 1.17 (0.46) 1.43 (0.37) 1.00E-02* 1.02 (0.58) 1.22 (0.47) 2.05E-01
Amp-Sokolow, mV 1.20 (1.05) 2.45 (0.80) 9.74E-07* 1.00 (0.75) 1.40 (1.10) 1.70E-01
Low-voltage limb (n) 11 (52.4%) 0 (0.0%) 7.41E-06* 6 (54.5%) 4 (40.0%) 1.00E+00
Low-voltage precordial (n) 2 (9.5%) 0 (0.0%) 1.65E-01 2 (18.2%) 0 (0.0%) 4.76E-01
Low-voltage Sokolow (n) 13 (61.9%) 0 (0.0%) 4.27E-07* 8 (72.7%) 5 (50.0%) 3.87E-01
Differences between cardiac amyloidosis patients (AL+ATTR) and controls as well as between AL and ATTR patients. AF indicates atrial fibrillation; AL indicates light-chain amyloidosis;
Amp, amplitude; ATTR, transthyretin amyloidosis; BBB, bundle branch block; QT, QT interval corrected for heart rate (Fridericia formula); RR and PR, RR, and PR intervals, respectively; TW,
T-wave.
*Statistically significant P-values.
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patients. Statistical analysis (Table 3) showed that AL
patients had lower epicardial signal amplitude (Figure 4,
1.07/0.46 versus 1.83/1.26 mV, P=0.02), a higher degree of
signal fractionation (Figure 4, maximum number of negative
deflections equal to 4.00/1.75 versus 3.00/1.00, P=0.02),
and longer (but nonsignificant) dispersion of repolarization
(Figure 4, DRT equals 187.6/65.1 versus 158.4/39.9 ms,
P=0.06) than ATTR patients.
Interactions Between EP and CMR Parameters
Correlation coefficients between ECGI and CMR parameters
are reported in Table 4. T1 was moderately correlated with
ECV (q=0.44, P=0.052) and inversely correlated with total
myocardial cell volume (q=0.54, P=0.014). A very high
(negative) correlation coefficient characterized the associa-
tion between T1 and epicardial signal amplitude (Figure 5A,
q=0.78, P<0.001). Signal amplitude also showed a moder-
ate correlation with total myocardial cell volume (q=0.48,
P=0.021) and T2 (q=0.45, P=0.039). ECV positively corre-
lated with signal fractionation (Figure 5B, q=0.48, P=0.032)
and showed a borderline significant correlation with repolar-
ization time (Figure 5C, q=0.43, P=0.058).
Accuracy of Automatic Classification Models
The univariate models showing higher accuracy in classifying
AL and ATTR patients used T2 (accuracy=81.0%) followed by
T1, Total Cell Volume, and LV mass (accuracy=71.4%) from
CMR, and epicardial signal amplitude (accuracy=71.4%) from
ECGI. There was no significant difference between the
accuracy provided by the best CMR univariate model and
that from the best ECGI univariate model (81.0% versus
71.4%, P=0.50). Penalized logistic regression using the least
absolute shrinkage and selection operator identified several
multivariate models with similar deviance. Among these,
those that used the fewest features included T2+DRT
(accuracy=85.7%) and T2+LV mass+DRT (accuracy=90.5%).
Figure 3. Example of a control (left), ATTR (center) and AL (right) patients showing marked differences in ECGI parameters, which are more
pronounced in the AL group. A through C, Epicardial signal amplitude is lower in cardiac amyloidosis vs control and lower in AL vs ATTR. D
through F, Total activation time (DAT) is longer in cardiac amyloidosis than in controls. G through I, Dispersion of repolarization (color coded as
the difference between local and minimum repolarization time) is higher in cardiac amyloidosis vs control and higher in AL vs ATTR. J through L,
Signal fractionation, measured as number of negative deflections in the QRS complex of the unipolar electrogram, is more elevated in AL
patients. AL indicates light-chain amyloidosis; Amp, amplitude; ATTR, transthyretin amyloidosis; ECGI, ECG imaging; Frac, fractionation; RT,
repolarization time.
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The difference in accuracy with respect to the best univariate
model was nonsignificant (P>0.37).
Discussion
This study combined CMR and ECGI for the first time to
simultaneously investigate the interaction between struc-
tural and EP substrates in cardiac AL and ATTR patients. In
particular, the utilization of ECGI allowed noninvasive
mapping of ventricular extracellular potentials for the first
time, as the only 2 previous EP studies were confined to
atrial mapping.33,34 The main findings were these. (1)
Cardiac amyloidosis patients have EP abnormalities that
include slow and spatially heterogeneous ventricular con-
duction, prolonged and spatially dispersed repolarization, as
well as low-amplitude epicardial potentials. (2) Despite
having lower total myocardial amyloid volume, AL patients
display more notable EP abnormalities compared with ATTR
patients, including lower epicardial signal voltage, higher
degree of signal fractionation, and slightly higher dispersion
of repolarization. (3) Signal amplitude showed a strong
inverse correlation with T1, whereas both signal fractiona-
tion and repolarization time increased with ECV. (4)
Univariate models based on single features from both
CMR and ECGI classified AL and ATTR patients with an
accuracy of 70% to 80%, and the best bivariate model
included both CMR and ECGI features (T2 and DRT) and
showed 85.7% accuracy.
These findings may have implications in identifying those
patients potentially at risk of conduction disturbances and
ventricular arrhythmias during active treatment. Indeed,
implantable loop recorder studies show a significant incidence
of complete heart block before the demise of AL patients2 as
well as cases of ventricular tachycardia.1,3,35,36
Results from surface ECG analysis showed differences
between cardiac amyloid and control patients in line with
previous findings.30,37-42 Interestingly, standard surface ECG
parameters were not different between AL and ATTR patients,
whereas ECGI was able to identify significant ventricular
conduction and repolarization differences between the 2
cardiac amyloidosis types, suggesting that ECGI parameters
may enable a better discrimination between AL and ATTR and
may improve risk stratification for ventricular arrhythmias.
Furthermore, ECGI analysis detected a significant prolonga-
tion of the ARI (a surrogate for action potential duration) and
its spatial distribution in cardiac amyloidosis. This was missed
by standard surface ECG analysis, which suggested that QTc
prolongation could be explained by QRS widening. Combined
ECGI-CMR analysis showed that epicardial signal amplitude
inversely correlated with T1 and T2, a measure of myocardial
edema,12 and positively correlated with total myocardial cell
volume. The strong inverse correlation between native T1 and
epicardial signal amplitude is interesting, as native T1 is a
Table 3. ECG Imaging Parameters
ECGI Parameters Amyloidosis (n=21) Controls (N=30) P Value Amyloidosis AL (n=11) Amyloidosis ATTR (n=11) P Value
Age, y 73.00 (19.25) 31.45 (31.55) 9.11E-07* 64.0 (8.5) 80.5 (7.0) 1.11E-02*
HR, bpm 74.61 (20.71) 58.99 (10.86) 6.39E-03* 78.4 (22.0) 67.4 (19.2) 3.42E-01
Amp, mV 1.15 (0.82) 1.96 (0.89) 4.14E-04* 1.07 (0.46) 1.83 (1.26) 2.65E-02*
Frac (n) 1.18 (0.11) 1.10 (0.10) 1.97E-04* 1.24 (0.12) 1.18 (0.18) 1.93E-01
mFrac (n) 3.00 (1.00) 3.00 (1.00) 8.29E-02 4.00 (1.75) 3.00 (1.00) 1.95E-02*
DAT, ms 65.43 (24.66) 41.50 (11.72) 7.50E-07* 65.9 (26.9) 60.3 (17.6) 8.33E-01
AT, ms 30.78 (6.99) 22.25 (10.00) 4.39E-05* 30.2 (10.3) 30.9 (7.3) 3.79E-01
DRT, ms 166.92 (41.35) 129.22 (24.34) 4.04E-05* 187.6 (65.1) 158.4 (39.9) 6.20E-02
RT, ms 318.17 (33.91) 272.27 (18.84) 7.91E-09* 310.8 (46.4) 320.6 (27.7) 4.18E-01
DARI, ms 180.22 (63.00) 143.23 (19.64) 4.14E-04* 192.0 (71.7) 162.1 (54.3) 1.49E-01
ARI, ms 283.22 (23.41) 242.62 (24.79) 4.14E-07* 281.9 (42.9) 288.1 (19.6) 6.99E-01
GAT, ms/mm 0.35 (0.14) 0.23 (0.08) 1.48E-06* 0.35 (0.13) 0.35 (0.14) 8.60E-01
GRT, ms/mm 0.85 (0.32) 0.94 (0.22) 4.38E-01 0.90 (0.33) 0.76 (0.33) 2.18E-01
Repolarization parameters were corrected for heart rate. AL indicates light-chain amyloidosis; Amp, mean epicardial signal amplitude; AT, RT, ARI, mean activation, repolarization, and
activation-recovery interval, respectively; ATTR, transthyretin amyloidosis; ECGI, ECG imaging; Frac, mean number of negative deflections in fractionated QRS complexes; GAT and GRT,
spatial gradients of activation and repolarization; HR, heart rate; mFrac, maximum number of deflections in fractionated QRS complexes; DAT, DRT, DARI, dispersion of activation,
repolarization, and ARI, respectively.
*P<0.05.
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combined signal from the intra- and extracellular space, and,
as such, it is influenced by both amyloid deposits and
myocardial edema (thought to be secondary to the light chain
toxicity/high rate of amyloid deposition), the 2 main patho-
physiological mechanisms linked to disease progression in AL
amyloidosis.8,9 Native T1 and epicardial signal voltage may be
epiphenomena of a similar underlying process, and future
studies should investigate whether their simultaneous assess-
ment may increase prognostic accuracy.
Our finding that cardiac amyloidosis is associated with
enhanced spatial gradients of activation suggests the
existence of disturbances in electrical conduction at the
tissue level, which was also reflected by a higher incidence
and complexity of epicardial signal fractionation in cardiac
amyloidosis versus control patients. A positive correlation
between ECV and signal fractionation suggests a link
between disturbances in electrical conduction and extracel-
lular deposition. However, the lack of direct correlation
between ECV and activation time may indicate that the
interaction between ECV and conduction is complex and
possibly modulated at the tissue level by the spatial
distribution of amyloid deposition. Interestingly, ECV also
correlated with average repolarization time, suggesting that
amyloid deposition may be directly implicated in the
abnormal prolongation of ventricular repolarization demon-
strated in this study and previously reported in cardiac
amyloidosis.43,44 The fact that both activation-recovery
interval and its spatial dispersion were significantly longer
in cardiac amyloidosis than in controls suggests that
abnormal repolarization patterns may be largely indepen-
dent of conduction abnormalities.
Our results show that although ATTR patients had higher
amyloid volume than AL patients, the latter were characterized
by more severe EP abnormalities. This supports the hypothesis
that additional mechanisms beyond amyloid infiltration may
contribute to the greater mortality in AL amyloidosis, such as
light chain toxicity,9 previously proven by in vitro studies, or
faster rate of amyloid deposition.8 In particular, ECGI data
suggest that AL patients were characterized by more spatially
heterogeneous conduction and repolarization than ATTR.
Spatial conduction-repolarization heterogeneity is a marker of
both increased arrhythmic and pump failure risk45-47 and may
be related to worse prognosis and a higher incidence of sudden
cardiac death in AL versus ATTR patients.
Table 4. Correlation Coefficients Between CMR-CMR and CMR-ECGI Parameters





Total cell volume 0.15 0.54* 0.23
Total amyloid volume 0.46* 0.02 0.17 0.16
CMR-ECGI
Amp 0.32 0.78* 0.45 0.48* 0.05
Frac 0.48* 0.22 0.09 0.32 0.33
mFrac 0.35 0.26 0.22 0.44* 0.08
DAT 0.03 0.04 0.09 0.09 0.33
AT 0.02 0.13 0.09 0.41* 0.07
DRT 0.29 0.02 0.03 0.18 0.17
RT 0.43* 0.34 0.20 0.22 0.29
DARI 0.18 0.01 0.20 0.12 0.10
ARI 0.36 0.39 0.07 0.06 0.27
GAT 0.11 0.08 0.02 0.08 0.24
GRT 0.19 0.10 0.06 0.11 0.25
Repolarization parameters were corrected for heart rate. Parameters were calculated using anatomical segments in common with both technologies. Amp indicates mean epicardial signal
amplitude; AT, RT, and ARI, mean activation, repolarization, and activation-repolarization interval, respectively; CMR, cardiac magnetic resonance imaging; ECGI, ECG imaging; ECV, mean
extracellular volume; Frac, mean number of negative deflections in fractionated QRS complexes; GAT and GRT, spatial gradients of activation and repolarization; mFrac, maximum number of
deflections in fractionated QRS complexes; DAT, DRT, DARI, dispersion of activation, repolarization and ARI, respectively.
*Statistically significant correlations.
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Future studies based on larger cohorts are needed to
determine whether this integrated analysis of both structural
and electrophysiological substrates could better capture the
disease complexity and provide additional insights for the
development of personalized prognostic and therapeutic
strategies.
Limitations
This was an exploratory study and the assessment of the
clinical impact of combining CMR and ECGI for the manage-
ment of cardiac amyloidosis patients should be determined in
specifically designed confirmatory studies. At this stage,
classification analysis was not performed with the aim to
propose and validate a specific diagnostic model but to
demonstrate that ECGI and CMR provide complementary
information that may be useful to better characterize AL and
ATTR substrate and risk profile. Because this is the first study
to have combined ECGI and CMR in cardiac amyloidosis, it
was not possible to test the classification model on another
data set, but standard leave-1-out cross validation was
performed to reduce overfitting. Furthermore, the study
cohort was small, and the within-group variability of some
variables was relatively high. However, the results of CMR and
surface ECG analysis are in line with previous find-
ings.5,7,14,30,37-42 Although a similar ECV between AL and
ATTR groups could indicate that patients were studied at a
similar stage of the disease, it may be possible that part of the
differences observed between AL and ATTR patients were
caused by the disease progression at the time of the study.
Recent studies have reported conflicting results about the
accuracy of a commercial ECGI system,48,49 and the utilization
of noninvasively computed as opposed to invasively measured
potentials in this study may have affected the results.
However, in this study we have used a noncommercial
system that has undergone extensive validation,50-52 and
electrograms were carefully analyzed and revised semiauto-
matically as in previous studies.25,26 Because ECGI measures
epicardial potentials, correlation between ECGI and CMR
parameters were investigated excluding septal segments.
Although EP differences between cardiac amyloidosis and
controls could be partially explained by age, all differences in
ECGI parameters remained significant between age-matched
subgroups, suggesting that EP abnormalities cannot be
entirely explained by age. Future studies should investigate
the differences in electrophysiological parameters after
adjustment for other confounders, such as medication,
comorbidity, and standard cardiovascular risk factors.
Conclusions
This study shows that cardiac amyloidosis is associated with
both ventricular conduction and repolarization abnormalities,
which are more pronounced in cardiac AL than in ATTR
patients. This represents a first step toward the integration of
structural and EP parameters for a better pathophysiological
characterization and more accurate arrhythmia and sudden
cardiac death risk stratification in this population.
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Table S1. Patients’ age, sex, aetiology and medication. 
  Sex Age Aetiology Medication 
1 M 85 TTR 
Apixaban 5mg bd, Tamsulosin 400mcg od, Lansoprazole 15mg 
od, Atorvastatin 10mg od, Doxycycline 100mg bd, Furosemide 
80mg bd, Spironolactone 50mg od 
2 M 68 AL  
Ranolazine 500mg bd, Amiodarone 100mg od, Furosemide 
40mg bd, Ramipril 1.25mg od, Omeprazole 20mg od, 
Rivaroxaban 20mg od, Questerinhaler 
3 M 77 TTR  
Bisoprolol 1.25mg od, Solifenacin 10mg od, Tamsulosin 
400mcg, Doxazosin 4mg od, Atorvastatin 10mg od, 
Amlodipine 5mg od, Fisateride 5mg od, Aspirin 75mg od, 
Ramipril 10mg od, Bisacodyl 10mg od 
4 M 86 TTR  Rivaroxaban 
5 F 65 AL 
Bumetanide 3mg bd, Simvastatin 40mg od, Mirtazapine 15mg 
od, Zopiclone 7.5mg od 
6 M 47 TTR  
Furosemide, Atorvastatin, Amlodipine, Omeprazole, Glicazide, 
Metformin, Empagliflozin 
7 M 59 AL 
Bumetanide 1mg, Spironolactone 50mg od, Doxycycline 
100mg bd, Rivaroxaban 
8 M 73 TTR 
Tildiem 200mg od, Rivaroxaban 20mg od, Ramipril 1.25mg od, 
Spironolactone 25mg od, Gabapentin 1 tds 
9 M 80 TTR  Goserelin 10.8mg every three months, Accrete D-3 
10 M 72 AL 
Aspirin 75mg, Furosemide 40mg od, Valsartan 320mg od, 
Atorvastatin 40mg od 
11 M 74 AL 
Rivaroxaban, Atorvastatin, Ramipril 1.25mg, Bisoprolol 7.5mg, 
Lansoprazole, B12 injections, Furosemide 40mg bd 
12 M 77 TTR  Furosemide 40mg od, Lansoprazole, Folica acid, Simvastatin 
13 M 85 TTR  
Ramipril 2.5mg, Simvastatin 40mg, Bisoprolol 2.5mg, 
Eplerenone 50mg, Warfarin, Lansoprazole 30mg, Furosemide 
40mg, Finasteride 5mg, Tamsulosin 400mcg 
14 M 82 TTR  Warfarin, Allopurinol, Candesartan, Atorvastatin 
15 M 83 TTR  Furosemide 40mg bd 
16 F 60 AL 
Thyroxine 75mcg od, Losartan 6.25mg bd, Co-Amiloride, 
Furosemide 40mg od, Citalopram 10mg od, Rosuvastatin 5 mg 
od 
17 M 85 AL 
Furosemide 40mg bd, Aspirin, Atorvastatin, GTN spray, 
Monomil XL 60mg od, Tamsulosin 400mcg od, Acyclovir 
400mg bd, Omeprazole 20mg od, Co-trimoxazole  
18 M 65 AL Ranitidine 150mg 
19 M 62 AL 
Valsartan 100mg bd, Levothyroxine 100mcg od, Rivaroxaban 
20mg od, Rosuvastatin 5mg od, Omeprazole 20mg od, 
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20 M 64 AL Apixaban, Bisoprolol, Furosemide 80mg bd, Atorvastatin 
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Table S2. 12 lead ECG parameters.  
 
Surface ECG Parameters 
Amyloidosis            
(Age Matched) 
n=10 
Controls          




Amyloidosis   




Age (years) 63.00 (17.00) 64.28 (8.18) 0.520 82.00 (16.00) 0.014 
AF (n) 1 (10.0%) 0 (0.0%) 1.0000 2 (18.2%) 1.0000 
RR (ms) 852 (182.0) 929 (312.0) 0.6232 900 (187.5) 0.2047 
QRS (ms) 107 (16.0) 88 (10.0) 0.0015 104 (35.0) 0.9437 
PR (ms) 172 (32.0) 166 (28.0) 0.3446 194 (73.5) 0.3608 
QTc (ms) 431 (53.6) 411 (14.7) 0.2123 452 (42.0) 0.1131 
Poor R progression (n) 9 (90.0%) 0 (0.0%) 0.0001 8 (72.7%) 0.5865 
BBB (n) 1 (10.0%) 0 (0.0%) 1.0000 2 (18.2%) 1.0000 
TW Inversion (n) 5 (50.0%) 0 (0.0%) 0.0325 3 (27.3%) 0.3870 
Amp-Limb (mV) 0.38 (0.22) 0.92 (0.33) 0.0009 0.40 (0.23) 0.6983 
Amp-Precordial  (mV) 1.04 (0.40) 1.34 (0.22) 0.0450 1.40 (0.51) 0.2907 
Amp-Sokolow  (mV) 1.05 (1.00) 2.40 (0.30) 0.0136 1.40 (1.02) 0.6981 
Low Voltage-Limb (n) 6 (60.0%) 0 (0.0%) 0.0108 5 (45.5%) 0.6699 
Low Voltage-Precordial (n) 1 (10.0%) 0 (0.0%) 1.0000 1 (9.1%) 1.0000 
Low Voltage-Sokolow (n) 7 (70.0%) 0 (0.0%) 0.0031 6 (54.5%) 0.6594 
 
Differences between the cardiac amyloidosis patients (first column) and controls (second column) 
matched by age. The third column shows differences between cardiac amyloidosis patients age-
matched to controls and the rest of cardiac amyloidosis patients. AF: Atrial fibrillation. QTc: QT 
interval corrected for heart rate (Fridericia’s formula); BBB: Bundle branch block; TW: T-wave; 
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Table S3. ECGI Parameters.  
ECGI 
Parameters 
Amyloidosis            
(Age Matched) 
n=10 
Controls          
(Age Matched)    
n=10 
P-value 
Amyloidosis   
(Rest of patients) 
n=11 
P-value 
Age (years) 63.00 (17.00) 64.28 (8.18) 0.520 82.00 (16.00) 0.014 
HR (bpm) 77.46 (16.62) 67.64 (28.49) 0.970 65.05 (19.89) 0.418 
Amp (mV) 1.11 (0.25) 1.96 (0.87) 0.014 1.60 (0.83) 0.170 
Frac (n) 1.21 (0.09) 1.10 (0.13) 0.004 1.18 (0.18) 0.418 
mFrac (n) 3.00 (2.00) 3.00 (1.00) 0.401 3.00 (1.00) 0.630 
ΔAT (ms) 60.30 (16.11) 42.97 (8.30) 0.005 68.36 (37.48) 0.275 
AT (ms) 30.46 (5.10) 25.17 (4.73) 0.045 30.93 (10.51) 0.647 
ΔRT (ms) 168.93 (37.28) 129.29 (33.50) 0.006 163.23 (45.56) 0.916 
RT (ms) 309.09 (31.96) 273.46 (14.26) 0.001 328.05 (35.58) 0.130 
ΔARI (ms) 177.61 (53.43) 136.55 (36.77) 0.026 191.97 (63.19) 0.549 
ARI (ms) 278.11 (34.47) 245.14 (12.49) 0.007 290.73 (22.80) 0.130 
GAT (ms/mm) 0.34 (0.05) 0.24 (0.07) 0.005 0.39 (0.18) 0.379 
GRT (ms/mm) 0.94 (0.62) 0.75 (0.21) 0.089 0.80 (0.32) 0.218 
  
Differences between the cardiac amyloidosis patients (first column) and controls (second column) 
matched by age. The third column shows differences between cardiac amyloidosis patients age-
matched to controls and the rest of cardiac amyloidosis patients. Amp: Mean epicardial signal 
amplitude; Frac: Mean number of negative deflections in fractionated QRS complexes; Frac-m: 
Maximum number of deflections in fractionated QRS complexes; AT, RT, ARI: Mean activation, 
repolarization and ARI, respectively.  ΔAT, ΔRT, ΔARI: Dispersion of activation, repolarization and 
ARI, respectively. GAT and GRT: Spatial dispersion of activation and repolarization. Repolarization 
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